Overview
Cardiogen is a synthetic tetrapeptide developed within Vladimir Khavinson's peptide bioregulator research programme at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a "cardiac muscle bioregulator" — one of a family of very short peptides Khavinson's group designed to mimic naturally occurring tissue-specific regulatory peptides, on the theory that each organ produces its own short peptide signals that decline with age. Cardiogen's proposed target tissue is cardiac muscle, and it is studied within this programme for research on cardiac cell differentiation and cardiac tissue support in preclinical models.
Important disambiguation: This page discusses the Khavinson-programme research peptide bioregulator called Cardiogen. It is entirely unrelated to a separate product also marketed under the name "Cardiogen" as an Indian pharmaceutical brand for cardiac medications (such as trimetazidine-based products sold in the Indian market). The two share a name only — they are different substances from different manufacturers with different regulatory histories. Nothing on this page refers to, endorses, or provides information about that unrelated Indian pharmaceutical brand.
It is important to state plainly what the evidence base for the Khavinson-programme Cardiogen peptide actually looks like: almost all published research originates from Khavinson's own laboratories or closely affiliated Russian institutions, published largely in Russian-language journals or their English-language sister publications (e.g.
Bulletin of Experimental Biology and Medicine,
Advances in Gerontology). There is no independent Western replication, no registered Western clinical trial, and no regulatory approval for Cardiogen as a medicine in the EU, UK, or Ireland. Readers should treat the findings below as a specific, narrow research literature — not as consensus science — and weigh that context heavily.
Within that literature, Cardiogen is studied mainly in preclinical cardiac tissue and cell culture models for effects on cardiac cell differentiation, markers of cardiac tissue ageing, and general research interest in cardiac-tissue-specific bioregulation. This guide is for educational and research purposes only. Not medical advice.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT (Western) |
✗ |
| Human RCT (Russian, small-scale) |
✔ (very limited) |
| Animal Studies |
✔ |
| In Vitro |
✔ |
| Regulatory Approval (Ireland/EU) |
✗ |
Mechanism of Action
Cardiogen's proposed mechanism is not receptor-based in the way conventional pharmaceuticals are described. Khavinson's peptide bioregulator theory proposes that very short peptides (2-4 amino acids) can interact directly with gene promoter regions or chromatin, modulating transcription of genes relevant to the tissue the peptide is derived from — in this case, cardiac muscle tissue. This is a substantially different and far less mechanistically established framework than classical receptor pharmacology.
Preclinical papers from the Khavinson group report that Cardiogen has been observed to support markers of cardiac cell differentiation and proliferation regulation in cultured cardiac tissue and in animal cardiac tissue samples, and to has been observed to support normalisation of certain age-related structural markers in cardiac muscle tissue of aged animal models. Proposed downstream effects include modulation of gene expression patterns associated with cardiomyocyte function and turnover. These mechanisms are reported almost exclusively by the originating research group and have not been independently confirmed through Western peer-reviewed replication.
Research Areas & Reported Effects
Cardiac Cell Differentiation Research
The bulk of Cardiogen-specific research relates to markers of cardiac muscle cell differentiation and regulation in preclinical cell culture and animal tissue models, given its classification as a cardiac-tissue bioregulator. Reported findings describe has been observed to support in differentiation-related gene expression markers in cardiac cell cultures following Cardiogen exposure.
Age-Related Cardiac Tissue Markers
Several Khavinson-affiliated papers report on Cardiogen administration in aged animal models, describing reported normalisation of certain structural and functional tissue markers in cardiac muscle relative to untreated aged controls. These findings are presented within the broader Khavinson bioregulator ageing framework rather than as cardiology-specific clinical outcomes.
General Cardiac Tissue Support in Preclinical Models
Preclinical literature describes Cardiogen's proposed role in supporting cardiac tissue resilience markers under experimental stress conditions in animal models. These are presented as exploratory findings within the originating research programme and have not been evaluated for clinical cardiac outcomes such as heart failure, arrhythmia, or ischaemic events.
Research Data Summary
| Study / Model |
Reported Effect |
| Cardiac Cell Culture Model (Khavinson et al.) |
Reported changes in cardiac cell differentiation-related gene expression markers. |
| Aged Rodent Cardiac Tissue Model |
Reported normalisation of select age-related structural tissue markers. |
| In Vitro Cardiomyocyte Culture |
Reported support of proliferation-regulation markers under experimental conditions. |
| Animal Cardiac Tissue Sampling Studies |
Reported observational tissue marker changes following Cardiogen exposure in preclinical models. |
Stack Combinations Studied
- Cardiogen + Cortagen → Research rationale: Both are Khavinson-programme tetrapeptides studied in adjacent organ-support research tracks; considered together in some Russian literature on multi-organ ageing support, though the combination itself is not a distinct study focus.
- Cardiogen + Ventfort → Research rationale: Ventfort is a Khavinson-programme peptide bioregulator associated with vascular tissue; the two are referenced together in Russian cardiovascular-ageing bioregulator literature as complementary cardiac/vascular tissue targets.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
Research Protocol Reference
experimental research protocols only — not dosing recommendations.
| Protocol |
Dose (experimental model only) |
Duration (experimental model only) |
Frequency (experimental model only) |
Research Context |
| Cell Culture Research Protocol |
Concentration-dependent, mcg/mL range reported in Russian in vitro literature |
Experiment-dependent, typically days |
Per experimental design |
Cardiac cell differentiation and gene expression marker studies. |
| Rodent Research Protocol |
Model-dependent, mcg/kg range reported in Russian literature |
10-20 days |
Once daily |
Age-related cardiac tissue marker studies in aged animal models. |
Observed Side Effects in Research
- No significant adverse events reported in the available Khavinson-affiliated literature
- Independent Western safety data is not available
- Cardiac-specific human safety and outcome data does not exist outside very limited Russian research settings
Because independent Western toxicology and cardiac safety studies have not been conducted, the absence of reported side effects in the existing literature should not be read as an established safety profile. This is especially relevant for a compound targeting cardiac tissue, where independent safety evaluation is particularly important.
Compound Data
- CAS Number
- Not reliably documented in Western chemical registries; no consistent CAS number is publicly established for this Khavinson-programme peptide
- Molecular Formula
- Not consistently published in Western chemical registries. Described in the originating literature as a short tetrapeptide; exact sequence and formula are not reliably cross-referenced outside Russian-language sources
- Molecular Weight
- Not consistently published in independently verifiable Western sources
- Half-Life
- Not established in independently published pharmacokinetic literature
- Synonyms
- Cardiac muscle bioregulator peptide (Khavinson programme). Not to be confused with the unrelated Indian pharmaceutical brand name "Cardiogen" used for other cardiac medications
- Research Classification
- Khavinson-class short peptide bioregulator, tissue-specific (cardiac muscle) research peptide
Scientific References
The references below are drawn from Vladimir Khavinson's peptide bioregulator research programme. Readers should note this evidence base is almost entirely Russian preclinical and very limited small-scale clinical research, published mainly in Russian-affiliated journals, and has not been replicated in Western randomised controlled trials. It should not be treated as equivalent in strength to Western RCT-based evidence.
- [Khavinson VK et al.] — Cardiac-tissue-specific short peptide bioregulators and markers of cardiomyocyte differentiation in preclinical models. — Bulletin of Experimental Biology and Medicine — [In vitro / Animal / Russian research programme]
- [Khavinson VK, Malinin VV] — Gerontological Aspects of Genome Peptide Regulation — Karger monograph — [Theoretical / mechanistic framework]
- [Ryzhak GA et al.] — Peptide bioregulators of cardiac and vascular tissue in age-related research models — Advances in Gerontology — [Animal]
- [Khavinson VK et al.] — Short peptide regulation of gene expression in cardiac and vascular tissue models — Neuroscience and Behavioral Physiology (affiliated series) — [Animal / Russian research programme]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*